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Abstract
Photochemotherapy is used both for solid tumors and in extracorporeal treatment of various hematologic disorders.
Nevertheless, its development in oncology remains limited, because of the low selectivity of photosensitizers (PS) towards
human tumor cells. To enhance PS efficiency, we recently covalently linked a porphyrin (TrMPyP) to a plant lectin (Morniga
G), known to recognize with high affinity tumor-associated T and Tn antigens. The conjugation allowed a quick uptake of PS
by Tn-positive Jurkat leukemia cells and efficient PS-induced phototoxicity. The present study was performed: (i) to evaluate
the targeting potential of the conjugate towards tumor and normal cells and its phototoxicity on various leukemia cells, (ii)
to investigate the mechanism of conjugate-mediated cell death. The conjugate: (i) strongly increased (61000) the PS
phototoxicity towards leukemic Jurkat T cells through an O-glycan-dependent process; (ii) specifically purged tumor cells
from a 1:1 mixture of Jurkat leukemia (Tn-positive) and healthy (Tn-negative) lymphocytes, preserving the activation
potential of healthy lymphocytes; (iii) was effective against various leukemic cell lines with distinct phenotypes, as well as
fresh human primary acute and chronic lymphoid leukemia cells; (iv) induced mostly a caspase-independent cell death,
which might be an advantage as tumor cells often resist caspase-dependent cell death. Altogether, the present
observations suggest that conjugation with plant lectins can allow targeting of photosensitizers towards aberrant
glycosylation of tumor cells, e.g. to purge leukemia cells from blood and to preserve the normal leukocytes in extracorporeal
photochemotherapy.
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Introduction
Extracorporeal photochemotherapy (ECP) is reported to be
effective for a wide variety of hematologic disorders, such as graft-
versus-host disease (GVH) or T cell lymphoma [1]. After
cytapheresis, mononuclear cells are treated with a photosensitizer
(PS), irradiated by ultraviolet-A (UV-A), and then reinfused to the
patient. Alternatively, photodynamic therapy (PDT) uses other PS
molecules and visible light to kill solid tumors [2]. Although the
molecular mechanisms induced by ECP and PDT partially differ,
both photochemotherapy (PCT) methods may be used to decrease
the tumor mass. In contrast to surgery, radiotherapy and
chemotherapy, PCT is known to stimulate the anti-cancer
immunity [3,4,5]. In addition, PCT can be effective against
chemo- and radio-resistant tumors [6].
So far, the relative poor selectivity of PS for tumor cells has
remained a major drawback for the development of PCT
applications. For instance, ECP efficacy could be increased
through targeting of PS to tumor cells, therefore sparing healthy
leukocytes, which would be reinfused to the patient with dead
malignant leukocytes. With respect to solid tumors, therapeutic
selectivity of PDT is achieved from the relative preferential
localization of PS in the tumor tissue, owing to its physicochemical
properties (e.g., hydrophobicity), and from the control of irradiated
areas (e.g., in dermatologic application). However, in complex
anatomical sites, such as the thoracic or abdominal cavities,
confined irradiation is more difficult and treatment may injure
normal tissue. Consequently, targeting of PS by increasing drug
concentration in tumor tissues must be sought to enhance PCT
efficacy.
Alterations of protein and lipid glycosylation at the cell surface
are consistent features of cancers. In tumors, aberrant glycosyla-
tion is responsible for incomplete synthesis of the carbohydate
chains, allowing higher expression of precursor carbohydrate
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antigens or (Galb1-3GalNAca1-O-Ser/Thr)/(GalNAca1-O-Ser/
Thr) epitopes] [7,8]. These glycopeptide antigens are associated
with many cancers and represent attractive candidates, among the
tumor-associated carbohydrate antigens, for the development of
anticancer immune stimulation [9] and drug targeting strategies
[10]. Thus, the preparation of anti-Tn antibodies has been
reported, but their evaluation in treatment or imaging of tumors is
generally inconsistent [10,11].
Along with antibodies, some plant lectins represent targeting-
vectors because of their capacity to specifically recognize sugars
and to distinguish subtle alterations in glycans on the cell surface
[12,13,14]. Thus, Morniga G (MorG), a hetero-tetrameric (a4b4)
lectin from Morus nigra was described as T/Tn (CD176/CD175)
antigen-specific in cell-free systems [15]. Consequently, this lectin
can be proposed for drug targeting towards tumor cells strongly
expressing T and/or Tn antigens. Recently, we have demonstrat-
ed that MorG can be specifically bound and taken-up by a Tn-
positive (Jurkat) lymphoid leukemia cell line [16]. For the first
time, the lectin was covalently conjugated to TrisMPyP (TrMPyP),
a cationic and hydrophilic porphyrin known to be white-light
activatable [17]. The TrMPyP-MorG conjugate was molecularly
characterized. The conjugate (with a 1:1 PS:lectin ratio) was
bound and quickly (5 min) taken-up by Jurkat cells. Preliminary
data indicate that the conjugate could trigger greater than 90%
phototoxicity on leukemic Jurkat cells at 10 nM concentration
[16]. In the present work, the role of O-glycosylation recognition
for the conjugate-induced phototoxicity was studied. Because of
the presence of CD175 and CD176 antigens on leukemia cells and
their absence on normal mature hematopoietic cells [7], the
conjugate-induced phototoxicity was comparatively evaluated
towards Jurkat leukemia T cells (CD175-positive) and healthy T
lymphocytes (CD175-negative). The phototoxicity of this new
conjugate was also tested against various human leukemia cell lines
and fresh primary leukemia cells from patients. Finally, the
mechanism of conjugate-mediated photoxicity was investigated.
Methods
Cells and reagents
Jurkat T, Molt 4, CEM, HuT78, K562, KG1, KG1a, HL60
and U937 leukemia cell lines (from ATCC), SKW6.4 cells (EBV-
transformed B lymphoid cell line, from ATCC) and ERG cells
(EBV-transformed B lymphoid cell line from our laboratory),
FADD-deficient Jurkat cells (from Dr. J. Blenis, Boston, MA,
USA), caspase 9-deficient Jurkat cells (from Dr. K. Shulze-Osthoff,
Du ¨sseldorf, Germany), Caspase 8- and 10-doubly deficient Jurkat
cells (from our laboratory [18]) were cultured in RPMI containing
10% FCS (Gibco, Cergy-Pontoise, France). Primary acute
lymphoid leukemia (ALL, pre-B phenotype for ALL1, ALL2,
and ALL3 and bi T/B phenotype for ALL4, T phenotype for
ALL5) samples were obtained from Tumorothe `que de Midi-
Pyre ´ne ´es (HIMIP, Inserm-U563, Purpan Hospital, Toulouse).
Primary chronic lymphoid leukemia (CLL, B phenotypes) and
healthy samples were obtained from Hematology department
(Rangueil Hospital, Toulouse). PBMC from healthy donors and
leukemic patients were separated using Ficoll-Paque Plus (Amer-
sham Biosciences, Piscataway, NJ, USA) density gradient. Normal
T lymphocytes were separated from PBMC using the Rosette Sep
human T cell enrichment cocktail (StemCell Technologies,
Grenoble, France) [14].
Morniga G (MorG) was purified from the bark of black mulberry
tree (Morus nigra) and labelled with FITC (Acros Organics, Fisher
Scientific, Illkirch, France) as previously described [14]. Anti-CD175
(anti-Tn) mAb and secondary PE-conjugated anti-mouse goat
polyclonal antibodies were from Acris Antibodies GmbH (Herford,
Germany). z-VAD(OMe)-fmk was purchased from Bachem (Voi-
sins-Le-Bretonneux, France). Mannan, Lactoferrin and Bovine
Submaxillary Mucin (BSM) were from Sigma-Aldrich (L’Isle
d’Abeau Chesnes, France).
Ethics statement
Fresh and thawed samples from ALL patients have been
obtained after informed consent and stored at the HIMIP
collection. According to the French law, HIMIP collection has
been declared to the Ministry of Higher Education and Research
(DC 2008-307 collection 1) and obtained a transfer agreement (AC
2008-129) after approbation by the ‘‘Comite ´ de Protection des
Personnes Sud-Ouest et Outremer II’’ (ethical committee).
Clinical and biological annotations of the samples have been
declared to the CNIL (Comite ´ National Informatique et Liberte ´s
ie Data processing and Liberties National Committee).
Blood samples from healthy donors and chronic lymphocytic
leukemia (CLL) patients were collected by Hematology depart-
ment (Rangueil Hospital, Toulouse), after patients’ written
informed consent in accordance with the Declaration of Helsinski.
For CLL, the samples were waste material took in diagnostic goal.
Preparation and characterization of TrMPyP-MorG
conjugates
TrisMPyP [5-(4-(5-carboxy-1-butoxy)-phenyl)-10,15,20-tris(4-
N-methyl)-pyridiniumyl-porphyrin] was synthesized and its N-
hydroxysuccinimidyl activated ester was prepared as described
previously [19], then TrMPyP-MorG conjugates were prepared
and characterized using SDS-PAGE analysis, MALDI-TOF mass
spectrometry analysis and spectrophotometry analysis [16]. A
TrMPyP-MorG conjugate with a mean of 1 PS per MorG lectin
molecule and without alteration of the sugar recognition specificity
of MorG was selected and used in the present experiments.
Photodynamic treatment and cell death evaluation
Cells (10
6/mL) were exposed to MorG, TrMPyP or TrMPyP-
MorG, with or without inhibitory sugar or glycoprotein solutions
for 15 min at 37uC, then washed. Because TrMPyP is white-light
activatable, cells were irradiated with a bank of four white
fluorescent tubes (Philips master TL-D 18W/840) for 7.5 min
(1.7 J/cm
2 light dose). Cell viability was evaluated using the MTT
reduction method (Euromedex, Souffelweyersheim, France) or by
flow cytometry using Annexin V-FITC and/or propidium iodide
staining (AbCys, Paris, France). The formation of acidic vesicular
organelles (AVOs, including autolysosomes) was evaluated by flow
cytometry using the pH-sensitive fluorescent dye acridine orange
(AO; Sigma). In viable cells, the concentration of AO in lysosomes
results in high red fluorescence. Starvation-induced autophagy
triggers an increase of red fluorescence of cells corresponding to an
increased number of AVOs [20]. Cell morphology was analyzed
using Syto 13 (Molecular Probes, Eugene, Oregon, USA) and
propidium iodide (PI) staining and a fluorescence-equipped
microscope (Olympus, SELI, Toulouse, France) as previously
described [21].
A mixture of freshly isolated healthy T lymphocytes and Jurkat
T cells was treated by photochemotherapy. The percentage of
each cell type was determined before and after PCT treatment by
flow cytometry, using the cell size and CD1d mAb staining (BD
Pharmingen, San Diego, CA, USA). T lymphocytes were defined
as CD1d-negative cells with low size and Jurkat T cells as CD1d-
positive cells with a greater size. In some experiments, 24 h after
Tumor Targeting in Photochemotherapy
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(1 mg/mL; clone L283, Becton Dickinson), anti-CD3 mAb (10 ng/
mL; Orthoclone, Janssen-Cilag, Issy-les-Moulineaux, France) and
Interleukin-2 (100 UI/mL; BD Pharmingen). Then, T lymphocyte
activation was checked by flow cytometry using a FITC-labelled
anti-CD25 mAb (BD Pharmingen) in the CD3+/CD1d- lympho-
cyte population.
Western blot analysis
Protein extracts (20 mg) were separated on SDS-PAGE and
blotted on nitrocellulose membranes. The blots were analyzed
using anti-cleaved PARP, anti-caspase 9 and anti-caspase 3, anti-
LC3B (Cell Signaling Technology, Danvers, MA) or anti-ß-actin
(Sigma) antibodies, as described elsewhere [22]. Proteins extracted
from FasL-treated Jurkat T cells served as a control for caspase-
dependent cell death [18] whereas those from Jurkat cells cultured
for 24 h in HBSS medium (without amino acids and FCS, Gibco)
were used as a control for starvation-induced autophagy [23]. To
quantify the bands obtained by Western blot analysis of LC3B
proteins, the ImageJ software (http://rsb.info.nih.gov/ij/) was
used. The ratio between areas under the curve (AUC) for LC3-II
and LC3-I was calculated for each condition.
ROS and ceramide production
ROS (Radical Oxygen Species) production was assessed as
previously described [24] using the H2DCFDA probe (Invitrogen,
Cergy Pontoise, France). Ceramide levels were measured as
previously reported [25], using recombinant DAG kinase
Figure 1. In vitro evaluation of O-glycan dependency of TrMPyP-MorG-mediated phototoxicity. Jurkat T cells (10
6/mL) were incubated
with various TrMPyP or TrMPyP-MorG concentrations for 15 min at 37uC in the dark. After washing, cells were irradiated (IR) or not (NI) by white light
for 7.5 min (allowing a 1.7 J/cm
2 light dose), and the cell viability was evaluated using MTT assay after 16 h incubation at 37uC in the dark. (A) Toxicity
of free TrMPyP. (B) Cells were incubated with or without TrMPyP-MorG in the presence of Bovine Submaxillary Mucin (BSM) or Mannan (1 mg/mL). Of
note, in the absence of irradiation no significant toxicity was observed at any TrMPyP-MorG concentrations (Anova test). (C) Protective effect of BSM
(1 mg/mL) as compared to Lactoferrin (a N-glycosylated glycoprotein, 1 mg/mL) and Mannan on TrMPyP-MorG (15 nM)-induced PCT. Results are
means 6 SD from 3–5 independent experiments. * P,0.001, Anova test, as compared to IR (as well as to IR+ Mannan or IR+ lactoferrin).
doi:10.1371/journal.pone.0023315.g001
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USA).
Statistical analysis
Results are expressed as the means 6 SD or SEM of data
obtained from at least 3 independent experiments. Statistical
significance, determined by means of Student’s t-test and/or
Anova test, was considered when P,0.05.
Results
The TrMPyP-MorG conjugate triggers O-glycan-
dependent cell death of Tn-positive Jurkat cells after
white-light irradiation
Previously, using various concentrations of TrMPyP-MorG we
demonstrated that a 10 nM concentration induced .90%
phototoxicity on Jurkat leukemia cells, whereas 10 nM of free
Figure 2. Effect of TrMPyP-MorG and PCT on a mixture of Jurkat leukemia T cells and healthy T lymphocytes. (A) T lymphocytes
isolated from healthy donors and Jurkat T cells were incubated with TrMPyP-MorG and irradiated as described in the legend to Figure 1. Three hours
after white light exposure (1.7 J/cm2), cells were stained by Annexin V-FITC and analyzed by flow cytometry. Results are means 6 SD of 3 independent
experiments. ** P,0.01and* P,0.05 as calculated using student t test. Applicationof Anovatestshowed a very significant (P=0.0026) difference in the
susceptibility of Jurkat and T lymphocytes to TrMPyP-MorG-induced phototoxicity. (B–D) T lymphocytes (10
6/mL) from healthy donors were mixed with
Jurkat T cells (10
6/mL), then treated or not by TrMPyP-MorG (15 nM) and white light (1.7 J/cm2). (B–C) The cell mixture was analyzed by flow cytometry
after 24 h culture. As compared to T lymphocytes, Jurkat T cells were characterized by a higher size and by CD1d positivity. (B) Representative
experiment, (C) means 6 SD of results from 4 independent experiments. T0 shows the percentage of the two cell types in the cell mixture before
TrMPyP-MorG addition. Significant changes (* P,0.001, Anova test) in cell percentage before andafter irradiation were observed. (D) 24 h post-PCT,the
TrMPyP-MorG treated cellmixturewasincubated for48 h with(emptyhistograms)or without(fullhistograms)IL-2+anti-CD3andanti-CD28monoclonal
antibodies. Then CD3+/CD1d- lymphocytes were analyzed by flow cytometry for CD25 expression as a marker for lymphocyte activation.
doi:10.1371/journal.pone.0023315.g002
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conjugate after PCT and (ii) the dependency of O-glycosylation
recognition for TrMPyP-MorG-mediated phototoxicity, cells were
incubated for 15 min with various conjugate concentrations and
with or without complex glycosylated molecules (Figure 1). Under
our experimental conditions, with or without white-light irradia-
tion, the free lectin seemed not toxic up to 1 mM (Figure S1).
While no toxicity was noticed after incubation with free porphyrin
or TrMPyP-MorG in the absence of irradiation (NI), a dose-
dependent cell death was observed with both agents after
irradiation (IR) (Figure 1A and B). Of special interest was the
finding that, whereas a LD50 close to 15 mM was observed for free
porphyrin (Figure 1A), a LD50 of 5 nM was found using the
TrMPyP-MorG complex (Figure 1B), indicating a porphyrin
phototoxicity increased by at least a factor of 1000. During
incubation with the conjugate, the addition of Bovine Submax-
illary Mucin (BSM) totally inhibited cell death, whereas addition of
mannan (a mannose polymer, Figure 1B) or lactoferrin (an only N-
glycosylated glycoprotein, Figure 1C) did not prevent Jurkat cell
death. Thus, because BSM is a glycoprotein containing high
density O-linked cryptic polyvalent T/Tn glycotopes, the
phototoxicity induced in Jurkat cell line by the TrMPyP-MorG
conjugate is probably dependent of O-glycosylation specific
recognition and probably of T/Tn antigens at the cell surface.
TrMPyP-MorG conjugate-mediated cytotoxicity allows
selective depletion of Jurkat cells and killing of various
leukemia cells
The T lymphocyte-surface glycosylation is modified during T-
cell development as well as T-cell activation [26] or oncogenesis
[27]. Human Jurkat leukemia cells are known to have a T
lymphocyte phenotype (for instance, they express a CD3 complex
and a a/b TCR) but an aberrant glycosylation. Indeed, its O-
glycosylation pattern is characterized by an overxepression of
CD175 antigen, i.e. Tn antigen, due to UDP-Gal:GalNAc a1-ser/
thr b1–3 galactosyl-transferase deficiency [28]. On the contrary,
normal T lymphocytes are CD175-negative [7]. To further
evaluate the targeting potential of the TrMPyP-MorG conjugate,
its toxicity was comparatively tested against Jurkat leukemia T cells
and isolated peripheral T lymphocytes. Previously, it was observed
that healthy T lymphocytes slightly bound a fluorescein-labelled
MorG whereas Jurkat leukemia T cells strongly bound it [16]. Of
particular interest was the finding that Jurkat leukemia T cells
were significantly more susceptible to PCT-induced cell death
than normal T cells at 5 nM (the LD50) and 15 nM concentrations
(Figure 2A), suggesting that the therapeutic index of the conjugate
could be sufficient to preserve healthy lymphocytes from
phototoxicity in the blood of leukemic patients, with the
perspective of extracorporeal photochemotherapy. When PCT
was applied to a 1:1 mixture of Jurkat T cells and T lymphocytes,
virtually all the leukemic cells were killed whereas healthy T cells
survived, at least during the 24 h post-treatment (Figure 2 B and
C). Of note, in the absence of irradiation, the percentage of
normal T-lymphocytes in the mixture decreased to 25% after 24 h
of culture, because Jurkat cells continued to grow while naı ¨ve
lymphocytes did not (Figure 2C). Interestingly, after irradiation the
healthy lymphocytes remained functionally competent, as CD25
expression increased 72 h after PCT upon immune stimulation
(Figure 2D).
Using hematopoietic cell lines of various origins, PDT-induced
toxicity of TrMPyP-MorG was directly correlated with the level of
FITC-labelled MorG binding [as evaluated at 4uC, as previously
described [16]] to the cells (Figure 3A). Two different sets of cell
lines could be distinguished. The first group with high MorG
Figure 3. Effect of TrMPyP-MorG and PCT on human hemato-
poietic cell lines and leukemia cell samples. Human cell lines or
fresh samples from patients with acute (ALL) or chronic (CLL) lymphoid
leukemia were treated with TrMPyP-MorG and white light (1.7 J/cm
2),
as previously indicated for Jurkat T cells, and cell viability was
determined using MTT assay 24 h after irradiation. Cell death is
expressed as a percentage of non-irradiated control cells. Concomi-
tantly, the binding (30 min at 4uC) to the cells of FITC-MorG (0.125 mg/
mL) was evaluated by flow cytometry (Mean flurorescence intensity
(MFI) was measured). (A) Correlation between lectin binding and
phototoxicity after treatment with 15 nM TrMPyP-MorG using Jurkat
(1), Molt 4 (3) and CEM (7) (T lymphoid leukemia cell lines), HuT78 (9) (a
Sezary T lymphoma cell line), ERG (4) and SKW 6.4 (6) (EBV-transformed
B lymphoid cell lines), KG1a (2), KG1 (5), HL60 (8), K562 (10), U937 (11)
(myeloid leukemia cell lines) cells. (B) Correlation between lectin
binding and phototoxic effect after treatment with 15 nM or 30 nM
TrMPyP-MorG of fresh primary ALL and CLL from five and four different
patients, respectively. Results are the means 6 SEM of 3–6
independent experiments for cell lines 1, 4, 9, 10 and 11, means of 2
independent experiments for other cell lines, and the mean of
quadruplicate determination for leukemia samples. r
2=linear correla-
tion index.
doi:10.1371/journal.pone.0023315.g003
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Jurkat and Molt4 cells (two T-lympoid leukemia cell lines), KG1
and KG1a (two myeloid leukemia cell lines) and ERG and
SKW6.4 cells (two EBV-transformed B lymphoid cells). The
second group showed little sensitivity or even resistance to
phototoxicity.
Because PCT is currently used in the clinic to treat T cell
lymphoma in ECP protocols, the conjugate was evaluated against
various lymphoid malignancies. The incubation of different acute
(ALL) or chronic (CLL) lymphoid leukemia primary cells from
patients confirmed that PCT-induced toxicity (as assessed by
MTT) increased with the TrMPyP-MorG dose and was
correlated with the level of MorG-binding on tumor cells,
supporting the notion that treatment efficiency mainly depends
on lectin-binding at the cell surface (Figure 3B). When the
number of patients’ primary leukemic cells was large enough, the
Figure 4. Cell death signaling triggered by PCT using TrMPyP-MorG conjugate. Jurkat T cells (10
6/mL) were incubated with various
TrMPyP-MorG concentrations for 15 min at 37uC and in the dark. After washing, cells were irradiated (IR) or not (NI), for 7.5 min. (A) Western blot
analysis of cells 3 h post-irradiation. FasL (50 ng/mL) was used as a control for inducing apoptosis. (B) Jurkat T cells were incubated in the presence
(+) or absence (2)o f2 0mM of the pan-caspase inhibitor (z-VAD), then treated by TrMPyP-MorG (15 nM) and irradiated (IR) or not (NI). FasL-induced
cell death was used as a control. Cell death was analyzed using MTT assay, 24 h after PCT. Results are means 6 SD of 4 separate experiments (similar
results were obtained with 5 nM TrMPyP-MorG), ** P,0.001, Anova test; NS, not significant. (C) Intracellular ceramide concentration was determined
3 h after PCT. Results are expressed as percentage of the ceramide levels in drug-treated controls without irradiation (mean of two separate
experiments; similar results were observed 24 h post-PCT). Cellular ROS levels were analyzed using flow cytometry. Representative results after
TrMPyP-MorG (5 nM) treatment and 15 min post-irradiation. (D) Three hours after irradiation, cells were stained with AnnexinV-FITC/PI (upper panel)
or Syto13/PI (lower panel) and cell death was evaluated by flow cytometry (in gate R1, defined to exclude cell debris from the analysis) or by
fluorescence microscopy, respectively. The arrow indicates a cell with classical features of apoptosis (reduction of cellular volume, nuclear
fragmentation, PI exclusion).
doi:10.1371/journal.pone.0023315.g004
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staining (Figure S2).
The TrMPyP-MorG conjugate kills Jurkat T leukemia cells
mainly through a caspase-independent pathway
To analyse the mechanisms of cell death triggered by the
conjugate, experiments were conducted to test whether an
apoptotic, caspase-dependent pathway was activated. As a control
for apoptosis, Jurkat cells were treated with FasL (and without
irradiation). Western blot analysis demonstrated the cleavage of
caspase 3 (effector caspase) and caspase 9 (initiator caspase) and
PARP (a nuclear target of effector caspase), indicating that
TrMPyP-MorG used in PCT triggered caspase activation
(Figure 4A). However, when a pan caspase-inhibitor (zVAD-fmk)
was added, no significant inhibition of cell death was observed,
suggesting the limited involvement of caspases in the phototoxic
effect of the conjugate (Figure 4B). Accordingly, variants of Jurkat
cells being deficient for different proteins of the caspase signalling
pathway [i.e. FADD (Fas-Associated protein with Death Domain)-
, caspase 9-, as well as caspase 8 and 10 doubly-deficient cells]
were not significantly protected from TrMPyP-MorG-induced cell
death, even though caspase 9-deficient Jurkat cells were resistant
to 5 nM, but not 15 nM, of conjugate (Figure 5). In addition,
TrMPyP-MorG conjugate-induced cell death was characterized
by an increase of both intracellular ROS and ceramide levels
(Figure 4C). Finally, TrMPyP-MorG induced cell death was
associated with: (i) phosphatidylserine externalization (i.e., Annex-
inV-FITC staining) (Figure 4D, high), (ii) membrane permeability
increase (i.e., PI staining), and (iii) a combination of morphological
features of necrosis (PI staining) and apoptosis (chromatin
condensation, nuclear fragmentation) (Figure 4D, bottom). When
TrMPyP-MorG-treated cells were stained with PI or acridine
orange (AO), the irradiation resulted in a strong PI staining
together with a decrease of AO fluorescence (Figure 6A). In normal
cells, when retained in lysosomes AO traps the protons and emits a
red fluorescence. Induction of autophagy is characterized by AVO
formation and an increased AO red fluorescence emission [20,23].
Our present findings suggest that the increase of plasma membrane
permeability is accompanied by a loss of lysosomal membrane
integrity and the release of the accumulated AO from lysosomes.
Nonetheless, under our experimental conditions, irradiation of
conjugate-treated cells induced a modest increase of LC3-II level,
known to be an autophagic marker (Figure 6B).
Discussion
The present data demonstrate that plant lectins could serve as
photosensitizer carrier proteins for the targeting of aberrant
glycosylation on tumor cells and, with regard to antibodies, as an
interesting additional weapon. Indeed, monoclonal antibodies are
the most successful binding molecules in biomedicine, but their use
is still limited in drug targeting, for instance by the difficulty and
expensiveness of manufacturing, and the relative instability under
conditions of covalent coupling with drug [29]. Conversely, the
structure of plant lectins confers strong resistance to heat and
chemical denaturing [12,13]. For instance, MorG presents a good
thermodynamic stability, partially due to the absence of cysteines
and consequently of disulfide bonds [30]. The extraction of the
lectin from the bark of black mulberry tree is relatively simple and
the chemical linkage with PS is easy. In addition, this lectin, as
others, could be probably prepared by bioengineering [31].
Finally, such a coupling with plant lectin appears to be
commercially realistic. With the aim to develop PS-targeting
strategy, different immunoconjugates have previously been
prepared between monoclonal antibodies [i.e., against colorectal
antigens [32,33] or HER2 antigen [34,35]] and different PS
molecules. Obviously, PS immunoconjugates are more selective
for target cells than free PS, but can be less phototoxic on a per
mole basis [34,36]. On the contrary, the TrMPyP-MorG
conjugate used here strongly increased the PS phototoxicity, for
instance at least of 1000 times on Jurkat leukemia cells. In
addition, to our knowledge no conjugate has been prepared
between a PS and a monoclonal antibody against T/Tn antigens.
Yet, several anti-T and anti-Tn antibodies have been generated
but with inconsistent results in their anti-tumor activities. A
possible explanation is that previously prepared monoclonal
antibodies recognize a conformational epitope constituted both
by a peptide and an altered glycan, rather than the sole
oligosaccharide moiety [10]. Consequently, these monoclonal
antibodies can, at least partly, cross react with the target peptide
on normal cells having a normal glycosylation. In contrast, some
plant lectins, such as MorG have a high affinity for specific
carbohydrate structure, independently of the peptide that carries
the carbohydrate moiety structures. As altered glycans are over-
expressed on tumor cells, plant lectins represent a powerful tool to
discriminate between normal and cancer cells, by the mean of
their cell surface binding to certain glycotopes, e.g. clusters of T/
Tn antigens. Hence, our present data suggest that a plant lectin
could be used as an efficient carrier for PS targeting, specifically
into tumor cells expressing alterations of glycosylation, actually O-
glycosylation. As other lectins, MorG recognizes different sets of
glycotopes (high affinity to T and Tn structures), but can
discriminate between subtle glycosylation modifications [14,15],
for instance in the present work, alterations of cell surface
glycoconjugates between leukemic and healthy T lymphocytes.
Our observations demonstrate for the first time that coupling a
porphyrin with a plant lectin allows the selective elimination of
leukemic cells mixed with healthy T cells, while fully preserving
the functionality of normal T cells. Using different hematopoietic
cell lines as well as primary lymphoid leukemia cells, the extent of
cell death induced by treatment correlated with the level of MorG
binding on target cells. Consequently, a useful tool to estimate the
tumor sensitivity to conjugate-mediated cytotoxicity might be the
Figure 5. Defects in the caspase signalling pathway do not
protect from TrMPyP-MorG conjugate phototoxicity. Parental
Jurkat T cells (Jurkat), FADD-deficient (D FADD), caspase 8- and 10-
doubly deficient (D casp 8–10) or caspase 9-deficient (D casp 9) Jurkat
cells (10
6/mL) were incubated with TrMPyP-MorG (5 or 15 nM) for
15 min at 37uC in the dark. After washing, cells were irradiated by white
light (7.5 min, 1.7 J/cm2) and the cell viability was evaluated using MTT
assay after 16 h incubation at 37uC in the dark. Results are means 6
SEM from 3–6 independent experiments, P*,0.05 as compared to
parental Jurkat T cells.
doi:10.1371/journal.pone.0023315.g005
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surface. However, in spite of a FITC-MorG binding lower than in
sensitive leukemic cell lines, some fresh lymphoid leukemia cells
were sensitive to the conjugate-mediated phototoxicity, quite
similarly to the sensitive established cell lines (Figure 3B). In
addition, because cell lines with T lymphoid, B lymphoid or
myeloid phenotype were similarly killed (Figure 3A), the present
data suggest that the susceptibility of leukemia cells to conjugate-
mediated toxicity is independent of the lymphoid or myeloid
phenotypes. The degree of sensitivity of tumor cells might be
related to the biochemical intracellular characteristics (such as
intrinsic resistance mechanisms to cell death) rather than to the
hematopoietic phenotype of leukemia cells. The results obtained
with fresh leukemia samples suggest that, as compared to ALL
cells, a higher binding of the lectin is required for killing CLL cells
by the MorG conjugate (Figure 3 and Figure S2). Because the
increase of ROS concentration is an essential step for PCT-
induced cell death using porphyrins [37], one possible explanation
might be that the status of oxidative stress and/or antioxidant
enzymes of ALL and CLL cells is different. ALL samples are
characterized by a decrease of anti-oxidants (for instance, a
decrease of catalase and superoxide dismutase activities [38,39])
and a sustained oxidative stress (due to a low NAD(P)H:quinone
oxidoreductase 1 activity, known to attenuate oxidative stress [40],
and/or aggressive chemotherapy protocols [38]). CLL are long-
lived cells in vivo, developing clonal resistance to apoptosis through
distinct mechanisms, such as overexpression of anti-apoptotic Bcl-
2 family members [41,42]. CLL cells also appear to have a
complex susceptibility to oxidative stress, being able to express and
release catalase extracellularly [43].
Figure 6. Induction of necrosis by TrMPyP-MorG conjugate. Parental Jurkat T cells (10
6/mL) were incubated with TrMPyP-MorG (5 or 15 nM)
for 15 min at 37uC in the dark. After washing, cells were irradiated (IR) or not (NI) by white light (7.5 min, 1.7 J/cm2) and incubated 3–4 h at 37uCi n
the dark. (A) The cell viability was evaluated using PI staining, whereas the formation of acidic vesicular organelles (AVO) was assessed by using
acridine orange. Cells were analyzed by flow cytometry excluding cell debris. Left, representative histograms: NI cells, full histograms; IR cells, empty
histograms. Right, means of two independent experiments. (B) Left, representative Western blot to detect the conversion of LC3-I to LC3-II. Right,
densitometry analysis; results are means of two independent experiments. Control cells (Ct) were cultured for 2 days either in RPMI medium
containing 10% FCS (2) or HBSS medium (without amino acids and FCS) (+), a condition known to induce autophagy and AVO formation.
doi:10.1371/journal.pone.0023315.g006
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MorG-induced toxicity after light irradiation, a previous work
indicates that cells quickly (5 min) took up the conjugate [16].
Whether only the internalized conjugate or, additionally, the cell
surface bound conjugate contributes to cytotoxicity needs to be
investigated. The present results suggest that caspase activation
was not absolutely required for efficient cell death after light
irradiation, as previously shown for FoscanH-mediated phototox-
icity [44]. It is possible that the conjugate triggers, in the same cell,
both caspase-independent and caspase-dependent events. Thus,
the PARP-1 dependent cell death program can be triggered by
ROS, independently of caspases [45,46]. In agreement with other
previous observations concerning the mechanisms of cytotoxicity
mediated by photoactivation of porphyrins or similar PS, treated
target cells exhibited an increase in ceramide and ROS
concentrations, two putative second messengers of cell death
[47,48], which can be involved in caspase-dependent and caspase-
independent cytotoxic processes [49]. The ROS are proposed as
the main agents triggering the demise process of tumor cells after
PDT [49]. They can kill tumor cells directly by apoptosis and/or
necrosis [50]. In the present work, the TrMPyP-MorG-mediated
phototoxicity was characterized by several necrosis features, such
as caspase-independence and plasma membrane permeability. In
addition, the decrease of AO staining induced by TrMPyP-MorG
treatment might be due to lysosomal disruption, in agreement with
recent data indicating that necrotic cell death can be characterized
by irreversible lysosomal permeabilization [51]. The elevated level
of LC3-II we observed might be compatible with a necrotic
process since necrosis-initiating insults can result in activation of
autophagy [52]. Thus, a main mechanism for TrMPyP-MorG-
mediated phototoxicity could be a necrotic cell death, at least in
Jurkat T cells. It is tempting to speculate that irradiation of
TrMPyP-MorG- treated cells might induce a strong oxidative
stress that triggers lysosomal membrane rupture and subsequent
necrosis, as proposed for neuronal death [52]. Finally, taken
together, our data suggest that PCT-induced toxicity using
TrMPyP-MorG can bypass the caspase pathway to trigger cell
death. This might be a valuable advantage over apoptosis-
inducing agents, since tumor cells often resist caspase-dependent
cell death [53].
ECP is currently used for treating T lymphoma (Sezary
lymphoma). This PCT method uses UV-A radiation and non-
targeted PS (psoralen) but does not preserve the healthy leukocytes
that are mixed with the malignant lymphocytes. The efficiency
and selectivity of PCT we observed using TrMPyP-MorG on a
mixture of leukemic and healthy cells suggest that this type of
conjugate could be advantageously employed in ECP against some
chronic hematopoietic malignancies. Indeed, the use of such
white-light activatable PS can allow lymphocyte preservation
because: i) the PS is targeted to cells exhibiting abnormal
glycosylation; ii) white-light is surely less toxic than UV on healthy
lymphocytes. Consequently, the new approach we describe could
be used in order to reduce the tumor mass and protect healthy
lymphocytes, preserving the ability of anti-tumor immune
response. Indeed, re-infusion of PCT-treated leukemic cells might
trigger auto-vaccination mechanisms [1,3,5]. In addition, the level
of Tn antigen expression and of MorG binding was significantly
higher on activated T lymphocytes than on resting T lymphocytes
(Figure S3), suggesting that PS-MorG conjugates might be used to
eliminate abnormal activated-lymphocytes by ECP. Indeed,
increasing amounts of observations indicate that ECP can be
useful to treat patients with autoimmune diseases or with chronic
graft versus host disease, which are all characterized by the
presence of abnormal activated-T cells [54].
In conclusion, whereas further in vivo experiments need to be
performed to document the efficiency of the PS-lectin conjugate,
the present observations demonstrate the potential of plant lectins
to target glycan alterations on tumor cells and to enhance the
delivery of photosensitizers in PCT in vitro, e.g. in ECP and
potentially in PDT. Plant lectins might also be used to increase
PDT efficiency against solid tumors, such as T/Tn positive
epithelial tumor cells. In addition, some plant lectins have specific
affinity for binding to the inflamed or non-inflamed endothelial
cells [55]. As targeting in PDT is mainly achieved today through
precise application of the light, conjugation of PS with a lectin able
to target tumor vasculature could enhance the efficiency of this
treatment in oncology.
Supporting Information
Figure S1 Toxicity of free MorG. Jurkat T cells (10
6/mL)
were exposed to various concentrations of MorG (from 5 to
5000 nM) for 15 min at 37uC, then washed. Cells were irradiated
(IR) or not (NI) as indicated in material and methods. Cell viability
was evaluated using MTT assay after 24 h of culture. Results are
means 6 SD of 3 independent experiments. The rectangle
corresponds to range of concentrations used for the evaluation of
conjugate phototoxicity in the present work. * P,0.05, as
compared to 5 or 100 nM TrMPyP-MorG.
(TIF)
Figure S2 The toxic effect of conjugate on fresh primary
leukemia cells was confirmed using annexin V-FITC/PI
staining and flow cytometry analysis. Fresh samples from
patients with acute (ALL) or chronic (CLL) lymphoid leukemia
were treated with TrMPyP-MorG and white light (1.7 J/cm
2), as
indicated in Figure 3. When the sample size permitted, the cell
viability was determined 3–4 hours after irradiation using
AnnexinV-FITC/PI staining and analysis by flow cytometry (in
gate R1, defined to exclude cell debris from the analysis or in gate
R2 defined as containing apparently viable cells, i.e. correspond-
ing to normal morphology of lymphocytes and lymphoblastes,
in size and granularity). (A and B) Representative experiment
analysis of a CLL sample : (A) in gate R1 and (B)i ng a t eR 2 .
Some fresh samples contained relatively high proportion of dead
cells, but allowed evaluation of conjugate-induced cell death
from the percentage determination of viable cells (defined as
AnnexinV-FITC and PI negative cells). (C and D) Correlation
between lectin binding and phototoxic effect after treatment with
15 nM or 30 nM TrMPyP-MorG of fresh primary ALL and CLL
from four and three different patients, respectively. Results are
the means of duplicate determination for each leukemia samples
in gate R2.
(TIF)
Figure S3 Comparative binding of MorG on resting T
lymphocytes and activated-T lymphocytes. T lymphocytes
isolated from healthy donors were incubated for 48 h with anti-
CD3 and anti-CD28 monoclonal antibodies and lymphocyte
activation was controlled using staining with anti-CD25 mono-
clonal antibody. Activated T cells, resting T cells from the same
donor and Jurkat T cells were incubated with FITC-MorG
(0.25 mg/mL) or anti-CD175 (anti-Tn) monoclonal antibody. (A)
Representative experiment, autofluorescence: full histograms,
positive fluorescence : empty histograms. (B) Mean fluorescence
intensity (MFI) was measured. Results for MorG staining are
shown, means of three experiments, Auto=autofluorescence,
*P,0.05 between resting and activated T cells.
(TIF)
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